Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Avadel Pharmaceuticals PLC
Other Current Liabilities
Avadel Pharmaceuticals PLC
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Other Current Liabilities
$5m
|
CAGR 3-Years
12%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-13%
|
|
|
Perrigo Company PLC
NYSE:PRGO
|
Other Current Liabilities
$47.6m
|
CAGR 3-Years
50%
|
CAGR 5-Years
40%
|
CAGR 10-Years
-3%
|
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Other Current Liabilities
$60.6m
|
CAGR 3-Years
96%
|
CAGR 5-Years
14%
|
CAGR 10-Years
35%
|
|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
Other Current Liabilities
$4.2m
|
CAGR 3-Years
16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Other Current Liabilities
€10m
|
CAGR 3-Years
3%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-6%
|
|
|
Ovoca Bio PLC
LSE:OVB
|
Other Current Liabilities
€159k
|
CAGR 3-Years
-41%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Avadel Pharmaceuticals PLC
Glance View
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 66 full-time employees. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.
See Also
What is Avadel Pharmaceuticals PLC's Other Current Liabilities?
Other Current Liabilities
5m
USD
Based on the financial report for Sep 30, 2025, Avadel Pharmaceuticals PLC's Other Current Liabilities amounts to 5m USD.
What is Avadel Pharmaceuticals PLC's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
-13%
Over the last year, the Other Current Liabilities growth was 2 041%. The average annual Other Current Liabilities growth rates for Avadel Pharmaceuticals PLC have been 12% over the past three years , -13% over the past five years , and -13% over the past ten years .
